ライフサイエンスコーパス: prognoses

1 particular among patients with initial worse prognoses.

2 effects in subgroups known to have different prognoses.

3 ern divides GBM in two groups with differing prognoses.

4 se, and renal disease have particularly poor prognoses.

5 izures but each is associated with different prognoses.

6 aggressive malignancies that have very poor prognoses.

7 amplification, which have particularly poor prognoses.

8 vein, lymph nodes, or lungs, leading to poor prognoses.

9 epressed patients who predominantly had poor prognoses.

10 y slides cannot accurately predict patients' prognoses.

11 be used to aid in establishing diagnoses and prognoses.

12 re similarities with breast tumors with good prognoses.

13 cation of subtypes associated with different prognoses.

14 e development of novel treatments and better prognoses.

15 atasets of human NE tumors with good or poor prognoses.

16 a strong cough, or who are awake have better prognoses.

17 y poor outcomes in a group with already poor prognoses.

18 normalities, gene expression signatures, and prognoses.

19 a diverse group of lung diseases with varied prognoses.

20 t birth and have only limited treatments and prognoses.

21 hort course in a group of patients with poor prognoses.

22 System intermediate-2/high, or >10% blasts) prognoses.

23 s (96.5%), physicians were able to formulate prognoses.

24 3%, P = .08) seemed associated with the best prognoses.

25 omparison of the formulated and communicated prognoses.

26 ovascular membranes having particularly poor prognoses.

27 hese levels with disease characteristics and prognoses.

28 and multiple sites associated with the worst prognoses.

29 ith heterogeneous clinical presentations and prognoses.

30 ves are needed for those with less favorable prognoses.

31 healthcare professionals estimate patients' prognoses.

32 as fixed abutments resulted in worse initial prognoses.

33 , includes four subtypes with very different prognoses.

34 pes of sepsis and ARDS that confer different prognoses.

35 patients diagnosed with cancers with poorer prognoses.

36 s and differences in beliefs about patients' prognoses.

37 CMO were critically ill with similar guarded prognoses.

38 eterogeneity correlates with cancer clinical prognoses.

39 any tumor types correlates with poor patient prognoses.

40 urvival forest was used to determine patient prognoses.

41 the oncogenic phenotype in tumors with poor prognoses.

42 eir children's developmental and psychiatric prognoses.

43 mmunomodulatory treatment and have different prognoses.

44 activation, DCBLD2 phosphorylation, and poor prognoses.

45 and multiple sites associated with the worst prognoses.

46 tion rates and suffered diminished long-term prognoses.

47 tcome assessment, therapeutic responses, and prognoses.

48 n particular among those with poorer initial prognoses.

49 revealed two classes with clearly different prognoses.

50 ts of MYC and either BCL2 or BCL6, face poor prognoses.

51 ents with varying clinical presentations and prognoses.

52 s, which could contribute to their divergent prognoses.

53 alpha (ERalpha)-positive tumors and disease prognoses.

54 ratify patients with significantly different prognoses.

55 d for individualizing therapy and predicting prognoses.

56 ed therapies for patients with SCC with poor prognoses.

57 lt acute myeloid leukemia patients with poor prognoses.

58 occurs in favorable and unfavorable disease prognoses.

59 where its expression is associated with poor prognoses.

60 natures were prominent in patients with good prognoses.

61 c NSCLC hold inaccurate perceptions of their prognoses.

62 essed in tumors from patients with favorable prognoses.

63 s were interviewed in the hospital to elicit prognoses.

64 ents often have different views of patients' prognoses.

65 ents were among patients with poorer initial prognoses.

66 to predict accurately the 5-year and 8-year prognoses 81% of the time.

67 nt clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in so

68 man IPF patients and is correlated with poor prognoses, advanced disease states and worse fibrotic ou

69 sly adequate cancer treatments and favorable prognoses, almost half of the patients experienced a pos

70 ve contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin combinations m

71 phenotype, explaining in part the disparate prognoses among medulloblastoma subtypes and suggesting

72 on was shown to strongly correlate with poor prognoses and decreased survival in pancreatic cancer pa

73 s about physicians' assessments of patients' prognoses and differences in beliefs about patients' pro

74 nd classifying tumors, as well as predicting prognoses and effective treatments.

75 be due to selection of patients with better prognoses and further stresses the importance of complet

76 f LGG that may identify patients with better prognoses and increased chance of responding to therapy.

77 aggressive malignancies associated with poor prognoses and limited treatment options.

78 learly identifies 3 subgroups with different prognoses and may be helpful for therapeutic decisions.

79 and are often associated with less favorable prognoses and outcomes.

80 analyses of cancer genomes promise to inform prognoses and precise cancer treatments.

81 type would improve accuracy in assignment of prognoses and prediction of tooth loss.

82 vance care planning, the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea

83 of 9,105 patients in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea

84 rticipating sites in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea

85 % women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea

86 of 9,105 patients in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea

87 Subjects were from the Study to Understand Prognoses and Preferences for Risks of Treatments (SUPPO

88 fter adjustment for differences in patients' prognoses and preferences, older age was associated with

89 to define disease subsets with more uniform prognoses and responses to therapy.

90 th localised disease can have very different prognoses and treatment options, ranging from observatio

91 These groups may have potentially different prognoses and treatment options.

92 ression models indicated that improvement in prognoses and worsening in prognoses were both strongly

93 Fifty-two were hematogenous, with poorer prognoses, and 88% were caused by methicillin-susceptibl

94 tically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknow

95 Patients' preferences and short-term prognoses are associated with the timing of DNR orders.

96 e clinical factors used in the assignment of prognoses are clearly associated with changes in clinica

97 Post-stroke prognoses are usually inductive, generalizing trends lea

98 ACAs have similar clinical presentations and prognoses as adults.

99 ess to care, HIV-infected women have similar prognoses as HIV-infected men.

100 ts with different immune response states and prognoses, as well as revealing the role of underlying g

101 el homeostasis contributing to the favorable prognoses associated with Th1-TME CRCs.

102 s made for sociodemographic characteristics, prognoses, baseline function, patients' preferences for

103 outcome of ALF varies by etiology, favorable prognoses being found with acetaminophen overdose, hepat

104 ver tissues from 56 HCC patients with better prognoses (BHCC, >/=5-year survival) and 58 with poor pr

105 new cases are thin (</= 1 mm) with favorable prognoses, but survival is nonetheless variable.

106 ts can improve the accuracy of diagnoses and prognoses, can improve the accuracy of genetic counselin

107 es; women using higher doses of nitrates had prognoses comparable with those of men.

108 creased accuracy, and more easily understood prognoses compared with conventional staging, allow for

109 e mechanisms underlying the observed adverse prognoses conferred by diagnosis of upper gastrointestin

110 e differing risk factor profiles and diverse prognoses demonstrate the potential importance of a stra

111 , skin-homing T lymphocytes and have varying prognoses depending on subtype and disease stage.

112 l nervous system tumors carry grave clinical prognoses due to limited effectiveness of surgical resec

113 may be preferred for patients with favorable prognoses, ECMO for patients with hemodynamic compromise

114 nced treatment regimens for iGAS may improve prognoses for obese patients.

115 trate characteristics predicting the poorest prognoses for patients requiring prolonged mechanical ve

116 strategies and the provision of quantitative prognoses for patients undergoing epilepsy surgery.

117 the identification of patients with distinct prognoses for stratification in clinical trials.

118 r patients with metastatic melanoma improved prognoses for the future.

119 Factors that foster good prognoses for this increasingly common and often protrac

120 nkly" colony, which may associate with worse prognoses from biofilm-associated infections.

121 tive and specific means of providing medical prognoses from biomarker patterns.

122 han 10 years and cancers with very favorable prognoses (Gleason score of 3 or 4 and prostate-specific

123 fferential responses to treatment and varied prognoses have long suggested myriad underlying causes.

124 orted that their beliefs about the patients' prognoses hinged exclusively on prognostic information p

125 With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating

126 Given Van de Vliert's impressive dataset and prognoses, I will discuss three limitations.

127 angements and can help patients with limited prognoses identify their end-of-life goals and preferenc

128 se had previously been associated with worse prognoses in autoimmune and viral hepatitis.

129 identify patients with the better and poorer prognoses in both of these risk group subsets.

130 phocytes (TILs) are correlated with positive prognoses in cancer patients and are used to determine t

131 trkB expression is associated with different prognoses in neuroblastoma, our study indicates that the

132 tive modality for following up and providing prognoses in patients with PAH.

133 thelial growth factor (VEGF) levels and poor prognoses in patients with solid tumors and acute leukem

134 G expression correlated with poorer clinical prognoses in several human cancers, and C/EBPgamma deple

135 Further analysis suggested better prognoses in the 12- to 18-month-old subgroup with hyper

136 knowledge when estimating their loved ones' prognoses, including individualized attributes of the pa

137 ributed to their beliefs about the patients' prognoses, including perceptions of the patient's indivi

138 that the traditional approach for assigning prognoses is ineffective for teeth with an initial progn

139 the acquisition of lymphomas with favorable prognoses is negated through an increased mortality from

140 ers in adolescence showed risks for negative prognoses lasting 20 years.

141 homa (ATL) are aggressive diseases with poor prognoses, limited therapeutic options, and no curative

142 ining treatments for patients with very poor prognoses may yield considerable cost savings.

143 resent study showed that teeth with hopeless prognoses might be retained by decreasing probing depths

144 al adenocarcinoma (PDA) has one of the worst prognoses of all cancers.

145 thyroid carcinoma (ATC) has among the worst prognoses of any solid malignancy.

146 Long-term prognoses of Axis I and Axis II disorders are of compara

147 s unclear whether statin use increases risk; prognoses of diabetes after exposure require further cla

148 vantages of the ITA.LI.CA staging system for prognoses of liver cancer developed by Alessandro Vitale

149 This study compared prognoses of myocardial infarction related to percutaneo

150 such as the superimposed acute illness, the prognoses of other patients cared for by the same physic

151 istologic classification system to determine prognoses of patients with alcoholic hepatitis (AH).

152 The CFF could help physicians determine prognoses of patients with cirrhosis.

153 igms to address the limited options and poor prognoses of patients with CUP.

154 ces treated with citric acid can enhance the prognoses of teeth with periodontal lesions as measured

155 epidemiology, clinical characteristics, and prognoses of the less common malignant diseases of the u

156 y to particular chemotherapeutic agents, and prognoses of these diseases.

157 escribed models are seldom used to determine prognoses of these patients, partially because they have

158 ncreatic cancer, assist in the diagnoses and prognoses of this disease, and develop novel therapies.

159 state cancers exhibited the poorest clinical prognoses on both univariable and multivariable analyses

160 ver, in a subgroup of CLL patients with good prognoses or early-stage disease (Rai stages 0-II, Binet

161 gs in this category may not have unfavorable prognoses over a period of 2 years when untreated.

162 ing depths (P < 0.0001), significantly worse prognoses (P < 0.0001), and significantly worse mobility

163 (BHCC, >/=5-year survival) and 58 with poor prognoses (PHCC, <5-year survival) after partial liver r

164 re associated with unfavorable and favorable prognoses, respectively.

165 rcations of multi-rooted teeth with hopeless prognoses seems to be a viable alternative to accessing

166 ed satellite lesions or local recurrence had prognoses similar to those of patients with stage III di

167 he first landmark but met the second one had prognoses similar to those who failed both landmarks.

168 cinomas, 10%-15% are mucinous and have worse prognoses than nonmucinous ones.

169 eloped IBTR or oLRR had significantly poorer prognoses than patients who did not experience these eve

170 microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but hav

171 Black patients have worse prognoses than whites with breast or colorectal cancer.

172 Patients referred to this bridge program had prognoses that are significantly better than those of pa

173 ent of a more effective method for assigning prognoses that is based on clear, objective clinical cri

174 ans identified uncertainty about recipients' prognoses, the perception that palliative care precludes

175 ukemia (AML) and confer relatively favorable prognoses, these cytogenetic groups are often treated si

176 pecifically described communicating terminal prognoses to patients only when specific preferences for

177 ventilation will help physicians communicate prognoses to patients or surrogate decision makers.

178 but promising step toward providing specific prognoses to patients, families, and practitioners.

179 s, to determine the relationship of assigned prognoses to the clinical criteria commonly used in the

180 cell lines representing cancers with dismal prognoses, tumor metastases, and multidrug resistant cel

181 ates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with

182 juvant therapy and are associated with worse prognoses.We investigated factors that might predispose

183 at improvement in prognoses and worsening in prognoses were both strongly associated with initial pro

184 erican Joint Committee on Cancer system, and prognoses were compared among different groups of the re

185 were not randomized, and patients with worse prognoses were disproportionately given the FA and TA re

186 When teeth with "good" prognoses were excluded, the predictive accuracy dropped

187 sicians who were least confident about their prognoses were more likely to favor no disclosure over f

188 ximately 60% spontaneous survival), and poor prognoses with drug-induced ALF, hepatitis B, and indete

189 ients with advanced CKD tended to have worse prognoses with elevated troponin I levels than those wit

190 the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL

191 valuating and comprehending nomogram-derived prognoses, with particular emphasis on clarifying common

192 iling identified AML patients with divergent prognoses within the FLT3-MU group, and the RUNX3 to ATR